Personalized emicizumab dosing for hemophilia A
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests whether adjusting emicizumab (Hemlibra) doses based on your body's drug levels can safely maintain good bleed control in people with hemophilia A who have been on the drug for at least a year.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hemophilia A (low factor 8 activity, less than 6 IU/mL).
- You are older than 1 year old.
- You have been on emicizumab (Hemlibra) for at least 12 months.
- You have had good bleeding control: no spontaneous joint or muscle bleeds in the last 6 months, and no more than 2 treated bleeds (from injury) in the last 6 months.
- You are willing to provide information about your bleeds and follow the dosing schedule.
- You (or your parent/guardian) can sign the consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a treatment called Altuviiio for children with severe hemophilia A who have developed inhibitors (antibodies that block factor replacement). The goal is to help the body become tolerant to factor therapy again, preventing bleeding episodes.
This trial studies Hemlibra (emicizumab) in people with mild congenital hemophilia A to see how well it works and what safety issues may occur. It may help reduce bleeding in patients who meet the study’s specific health and safety requirements.
This trial tests emicizumab, a medicine given under the skin, to see how it works in children with hemophilia A. It aims to help control bleeding, no matter if they have inhibitors or not.
This trial studies how your body’s anti-factor VIII antibodies change while you are treated with emicizumab for severe hemophilia A. The goal is to better understand the immune response during treatment and whether it relates to how well therapy works.
This trial compares two low-dose prophylactic treatments for severe hemophilia A. Patients receive either low-dose emicizumab or low-dose factor VIII to see which works better for preventing bleeding episodes.
This trial uses ultrasound to check if healthy joints in people with hemophilia A develop damage while being treated with emicizumab (Hemlibra). It looks at elbows, knees, and ankles over time to see if the medicine prevents joint problems.
Hear when a new Hemophilia A With Inhibitor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.